WASHINGTON, 14 June 2019:
While still experimental faecal transplants could supposedly bring about a variety of health benefits, the US Food and Drug Administration (FDA) yesterday issued a safety warning over the procedure after one patient died.
Another patient also fell ill after receiving a separate transplant, the FDA said, with the poo sample prepared from stool obtained from the same donor.
It noted the stool sample had not been tested for drug resistant E.coli bacteria – now recommending such screening be conducted as well before such procedures.
“While we support this area of scientific discovery, it’s important to note that FMT (faecal microbiota for transplantation) does not come without risk,” Dr Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement.
The FDA has permitted these experimental transplants to be conducted since 2013.